MRK
Merck exec says company is discussing use of COVID antiviral drug in Ebola response
Article Summary
HOLD- Merck & Co. (NYSE: MRCK) is in discussions with global health authorities about making its COVID antiviral pill molnupiravir available as an Ebola treatment to address widening outbreak in Democratic Republic of Congo, senior executive told Reuters.
- The outbreak has so far infected a suspected 1,100 people and resulted in 42 deaths, involving rare strain of Bundibugyo for which there are no approved vaccines or treatments.
- The pill, developed by the New Jersey-based drugmaker along with Ridgeback Biotherapeutics and sold under brand Lagevrio, was approved for emergency use by FDA during pandemic for mild-to-moderate COVID-19 in adults at high risk for severe disease.
- Although not an approved Ebola treatment, the drug has shown some efficacy against Ebola in animal studies and could be useful to prevent Ebola infections in high-risk individuals, though not recommended for use during pregnancy.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 2.7% | 25% | 20.0 ptsMinimal (2.7%) - Very weak |
| EPS Growth Next 5Y ? | 6.0% | 25% | 20.0 ptsWeak (6.0%) - Low expectations |
| Target Price Upside ? | 14.1% | 20% | 50.0 ptsMeets Minimum (14.1%) - Target: $131.83 vs Current: $115.53 |
| Gross Margin % ? | 73.4% | 15% | 100.0 ptsExceptional (73.4%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -7.7% | 15% | 20.0 ptsBarely a Dip (-7.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MRK
- Merck & Co., Inc. operates as a healthcare company worldwide.
- It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
- The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
- It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc.
- Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets.
- The company was founded in 1891 and is headquartered in Rahway, New Jersey.